1. Introduction {#sec1-1}
===============

Metabolic syndrome is an independent risk factor of cardiovascular disease (CVD) ^\[[@ref1],[@ref2]\]^ that is associated with high treatment costs, risk of disability ^\[[@ref3]\]^ and premature death in schizophrenia patients.^\[[@ref4]\]^ A recent meta-analysis found that the pooled prevalence of metabolic syndrome in patients with major psychiatric disorder was 32.6%, with higher rates in schizophrenia (33.4%) than bipolar disorder (31.7%) and major depression (31.3%).^\[[@ref5]\]^ Of the metabolic syndrome features, dyslipidemia, especially elevated low density lipoprotein cholesterol (LDL-C), is a major cause of CVD.^\[[@ref6]\]^ Thus, LDL-C lowering therapy could significantly reduce the risk of CVD.^\[[@ref9]\]^

Pharmacological and non-pharmacological treatments have been widely used for metabolic syndrome in schizophrenia. Of the pharmacotherapies, statins appeared to be the most effective in reducing the risk of ASCVD (atherosclerotic cardiovascular disease) by decreasing the biosynthesis of cholesterol.^\[[@ref7]\]^ As lipid-lowering drugs, statins mainly played a role in LDL-C subfraction.^\[[@ref10]\]^ A cohort study^\[[@ref8]\]^ found statins proved effective in improving dyslipidaemia in schizophrenia patients. Of them, rosuvastatin showed a large effect size in the management of dyslipidemia.^\[[@ref11]\]^ Several controlled studies ^\[[@ref6],[@ref12]\]^ have found that rosuvastatin is effective and safe in improving dyslipidemia in schizophrenia patients although the findings have been inconsistent.

To the best of our knowledge, no systematic review or meta-analyses of adjunctive rosuvastatin in treating dyslipidemia in patients with schizophrenia have been published. We thus conducted this meta-analysis of controlled studies to examine the efficacy and safety of adjunctive rosuvastatin for dyslipidemia in schizophrenia patients.

2. Methods {#sec1-2}
==========

2.1 Search Strategy and Selection Criteria {#sec2-1}
------------------------------------------

According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement ^\[[@ref15]\]^, English (PubMed, PsycINFO, and Cochrane Library) and Chinese (China Knowledge Network, WanFang Database and Chinese Biomedical Database) databases were systematically searched by two authors (WZ and D-BC) independently from their inception up to September 28, 2017 using the following search terms: (crestor OR rosuvastatin) AND (schizophrenic disorder OR disorder, schizophrenic OR schizophrenic disorders OR schizophrenia OR dementia praecox). Moreover, the references of the included studies and relevant reviews were also hand-searched for identifying any omitted trials.

Two authors (WZ and D-BC) independently assessed the eligibility of studies following the criteria of the *PICOS* acronym. Participants: adult patients with schizophrenia according to any diagnostic criteria. *I*ntervention: rosuvastatin plus antipsychotics. *C*omparison: antipsychotics plus placebo or antipsychotics monotherapy. *O*utcomes: The primary outcome measure was LDL-C (mg/dL). Secondary outcomes were total cholesterol (mg/dL), high density lipoprotein cholesterol (HDL-C, mg/dL), triglycerides (mg/dL), fasting glucose (mg/dL), body weight (kg), body mass index (BMI, kg/m^[@ref2]^), waist circumference (cm), improvement of psychotic symptoms as assessed by the Positive and Negative Syndrome Scale (PANSS) ^\[[@ref16]\]^ or Brief Psychiatric Rating Scale (BPRS) ^\[[@ref17]\]^, discontinuation due to any reasons and adverse drug reactions (ADRs). *S*tudy design: controlled studies with meta-analyzable data on the efficacy and safety of adjunctive rosuvastatin in improving dyslipidemia or other metabolic symptoms. Furthermore, the title of this meta-analysis are slightly different from the registered protocol; i.e., the registered title "rosuvastatin for dyslipidemia in schizophrenia: a metaanalysis" was revised to "meta-analysis of the efficacy and safety of adjunctive rosuvastatin for dyslipidemia in patients with schizophrenia".

2.2 Data extraction {#sec2-2}
-------------------

Data from the included studies were independently extracted and checked by two reviewers (X-HY and D-BC). When intention-to-treat (ITT) or modified ITT and observed cases data were reported concurrently, ITT or modified ITT data were preferred following the methodology of the previous meta-analysis.^\[[@ref18]\]^ The corresponding or first authors of the relevant studies were contacted for any unpublished data if needed.

2.3 Statistical methods {#sec2-3}
-----------------------

This meta-analysis was conducted using the random effects model of Review Manager software (version 5.3 for Windows) (<http://tech.cochrane.org/revman/>) due to potential heterogeneity across studies.^\[[@ref19]\]^ For continuous outcomes, standardized mean differences (SMDs) with the estimated effect size (Hedges' g) were calculated. For dichotomous outcomes, risk ratio (RR) with its 95% confidence intervals (CIs) was computed. The heterogeneity between studies was investigated by considering the I^[@ref2]^ method alongside the chi-squared statistics, with I-squared ≥ 50% or Chi-squared *p* value \< 0.1 as heterogeneity.^\[[@ref20]\]^ Moreover, a subgroup analysis (Chinese versus non-Chinese participants) was conducted. Finally, funnel plots and Egger's test ^\[[@ref21]\]^ were used to explore potential publication bias. All analyses were two tailed, with significance level set at 0.05.

2.4 Assessment of reporting biases {#sec2-4}
----------------------------------

The methodological quality of included studies were assessed using the Cochrane risk of bias ^\[[@ref22]\]^ and Jadad scale.^\[[@ref23]\]^ The grading of recommendations assessment, development, and evaluation (GRADE) system ranged from "very low", "low", "moderate", to "high" was used to interpret the overall quality level of the main outcomes of meta-analysis.^\[[@ref24],[@ref25]\]^

3. Results {#sec1-3}
==========

3.1 Results of the search {#sec2-5}
-------------------------

The initial literature search in English and Chinese databases yielded 13 electronic records ([Figure 1](#fig001){ref-type="fig"}). Duplication excluded 3 trials. Of the remaining 10 trials, 6 were determined to be irrelevant after review of the titles and abstracts, and zero were removed on the basis of full text review. In the end, 4 eligible studies ^\[[@ref6],[@ref12]\]^ were included in this meta-analysis.

3.2 Characteristics of included studies {#sec2-6}
---------------------------------------

The 4 studies (*n*=274, [Table 1](#table001){ref-type="table"}) included 3 randomized controlled trials (RCTs) (*n*=174) and one controlled study without randomization (n=100) that compared adjunctive rosuvastatin (*n*=138) and control groups (*n*=136). The weighted mean age was 39.3 years (range = 34.1-43.5 years), weighted mean percentage of males was 65.7% (range= 56.5% - 78.0%), and weighted mean illness duration was 12.0 years (range= 5.8 - 15.5 years). The weighted mean of treatment duration was 10.4 weeks (range= 8 - 12 weeks) ([Table 1](#table001){ref-type="table"}). Three RCTs were conducted in China (*n*=174), and one in Belgium (*n*=100). The dosage of rosuvastatin ranged from 5 to 10 mg/day. The baseline antipsychotics included clozapine (1 trial), olazapine or risperidone (1 trial), and mixed antipsychotics (2 trials). For example, De Hert et al's study ^\[[@ref6]\]^ included first-generation and second-generation antipsychotics (amisulpride, clozapine, risperidone, olanzapine, and quetiapine).

3.3 Study quality and GRADE assessment {#sec2-7}
--------------------------------------

In one study ^\[[@ref6]\]^ subjects were not randomized; the remaining 3 RCTs ^\[[@ref12]\]^ included two RCTs with double blinded design and one RCT ^\[[@ref12]\]^ with open label design. One RCT ^\[[@ref13]\]^ described randomization methods (i.e. the random number table), while selective reporting and other sources of bias were rated as having unclear risk in all RCTs (Supplemental Figure 1). In 3 RCTs, the weighted mean Jadad scores were 3.4 (range=2-5, [Table 1](#table001){ref-type="table"}). The quality of evidence for primary and secondary outcomes as assessed by the GRADE approach ranged from "very low" (35.3%) to "low" (64.7%) (Supplemental [Table 1](#table001){ref-type="table"}). Of them, the primary outcome (LDL-C) was rated as "very low".

3.4 Efficacy and safety {#sec2-8}
-----------------------

### 3.4.1 Primary outcome {#sec3-1}

Rosuvastatin group was superior to the control group regarding the effects on LDL-C \[4 trials, *n*=272, SMD: -1.31 (95%*CI*: -1.93, -0.70), *p* \< 0.001; *I^[@ref2]^* = 81°%, [Figure 2](#fig002){ref-type="fig"}\]. The significance remained after excluding one study without randomization ^\[[@ref6]\]^ \[3 trials, *n*=172, SMD:-1.07 (95% *CI* : -1.60, -0.53), *p* \< 0.001; *I^[@ref2]^* = 63%\]. The subgroup analysis found more positive effects of rosuvastatin in non-Chinese than Chinese studies (*p* = 0.01). As only 4 trials were analyzed for primary outcomes, publication bias of LDL-C could not be examined using funnel plot or Egger's test.^\[[@ref26]\]^

### 3.4.2 Secondary outcomes {#sec3-2}

Rosuvastatin group was also superior to the control group in terms of the effects on total cholesterol (2 trials, *n*=164, SMD: -2.00 (95%*CI* : -2.79, -1.21), *P* \< 0.001; *I^[@ref2]^* =76%) and triglycerides (2 trials, *n* = 164, SMD: -1.05 (95%*CI* :-1.38, -0.72), *p* \< 0.001; *I^[@ref2]^* =0%), but not in HDL-C (2 trials, *n* = 164, *SMD:* 0.14 (95*%CI:* -0.16, 0.45), *p* = 0.36; *I^[@ref2]^* =0%) ([Table 2](#table002){ref-type="table"}).

No significant differences in body weight (3 trials, *n* = 208, SMD: -0.40 (95%CI: -1.29, 0.49), *p* = 0.38; *I^[@ref2]^=*89%), BMI (2 trials, *n*=164, SMD: -0.34 (95%*CI* : -1.23, 0.56), *p* = 0.46; *I^[@ref2]^* = 87%), waist circumference (3 trials, *n* = 208, *SMD:* -0.43 (95*%CI:* -1.31, 0.46), *p* = 0.34; *I^[@ref2]^*=89%), and fasting glucose (4 trials, *n* = 272, SMD: -0.25 (95%*CI*: -0.65, 0.15), *p* = 0.23; *I^[@ref2]^* =62%) were found between rosuvastatin and the control group ([Table 2](#table002){ref-type="table"}).

Three studies measured the improvement of psychotic symptoms as assessed by the PANSS, but did not find any group difference (3 trials, *n* = 172, *SMD:* 0.05 (95%*CI*: -0.25, 0.34), *p* = 0.77; *I^[@ref2]^* =0%, [Table 2](#table002){ref-type="table"}).

Meta-analyses of ADRs including dizziness, dry mouth, insomnia, tachycardia, constipation, nausea/vomiting and extrapyramidal symptoms ([Table 2](#table002){ref-type="table"}) showed no significant differences between groups (p = 0.29 to 0.92). Discontinuation rates due to any reasons (2 trials, *n* = 128, *RR:* 1.99 (95%*CI*: 0.36, 11.08), *p* = 0.43; *I^[@ref2]^* =0%) were also similar between groups ([Table 2](#table002){ref-type="table"}).

4. Discussion {#sec1-4}
=============

4.1 Main findings {#sec2-9}
-----------------

To our knowledge, this is the first meta-analysis to examine the efficacy and safety of rosuvastatin as an adjunctive treatment for dyslipidemia in patients with schizophrenia. We found that adjunctive rosuvastatin could significantly improve LDL-C with "very low" evidence level based on GRADE assessment, total cholesterol, and triglycerides in schizophrenia patients treated with antipsychotics, which is consistent with previous findings.^\[[@ref27],[@ref28]\]^

4.2 Limitations {#sec2-10}
---------------

The following limitations should be acknowledged. First, a heterogeneous result regarding the primary outcome was found. Second, 4 trials with 274 patients were included, which limits more comprehensive analyses (i.e. meta-regression analysis). Third, the dose-response effect of rosuvastatin for dyslipidemia was not evaluated since the dosage of rosuvastatin varied across all studies (5 to 10 mg/day). Fourth, the data on categorical metabolic syndrome was only reported in one trial.^\[[@ref6]\]^ Fifth, this meta-analysis did not focus on RCTs only, which could decrease the validity of the findings. Sixth, long-term effects of adjunctive rosuvastatin beyond 12 weeks were not examined. The quality of the studies included in this meta-analysis was relatively low (such as one study without randomization) and the quality of evidence for primary outcome was rated as "low". Finally, the efficacy and safety of other statins for dyslipidemia in patients with schizophrenia need to be examined.

4.3 Implications {#sec2-11}
----------------

Due to the unhealthy lifestyle, irregular diet and need for long-term antipsychotics use in schizophrenia patients, the prevention and treatment of metabolic syndrome is a major challenge in clinical practice.^\[[@ref1]\]^ Other medications, such as metformin ^\[[@ref29]\]^ and topiramate ^\[[@ref30],[@ref31]\]^, have been shown to improve weight gain or BMI, however, such effects were not observed with rosuvastatin in this study.

Hanssens et al found statin treatment for schizophrenia patients was well tolerated except from one patient who suffered from abnormal liver enzymes and high CK levels.^\[[@ref8]\]^ Similarly, rosuvastatin appeared to be relatively safe and well-tolerated for schizophrenia patients in this meta-analysis. Previous studies have found that rosuvastatin is associated with increased risk of myotoxicity, ranging from muscle pain without CK elevation to renal failure ^\[[@ref32]\]^, and hepatotoxicity, ranging from asymptomatic transient elevations to liver failure.^\[[@ref33]\]^ However, none of these side effects were reported in the included studies with the exception of one study ^\[[@ref6]\]^ where a subject had abnormal liver enzyme.

5. Conclusion {#sec1-5}
=============

The data available on the effectiveness and safety of adjunctive rosuvastatin in treating dyslipidemia for patients with schizophrenia is insufficient to obtain a definitive interpretation about its efficacy and safety. Further high quality RCTs with extended treatment duration are warranted to confirm the findings.
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###### 

Study and patient characteristics of the included trials

  Study (country)          Number of patients[^a^](#tfn001){ref-type="table-fn"}   Randomized controlled trial   Trial Duration (wks)   Diagnosis Setting          Diagnostic criteria   Illness severity[^a^](#tfn001){ref-type="table-fn"}/duration[^a^](#tfn001){ref-type="table-fn"}   Age[^a^](#tfn001){ref-type="table-fn"}: yrs (range)   Sex[^a^](#tfn001){ref-type="table-fn"}: Male (%)   ROS: Dose (mg/d): mean (range)   Jadad score
  ------------------------ ------------------------------------------------------- ----------------------------- ---------------------- -------------------------- --------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------- -------------------------------------------------- -------------------------------- -------------
  De Hert 2006 (Belgium)   C: 48 I: 52                                             No                            12                     SCZ (80), SzA (20); Both   DSM-IV                -ND -13.1 yrs                                                                                     38.5 (ND)                                             78.0                                               Ø=10 (FD)                        NA
  Gao 2014 (China)         C: 33 I: 31                                             Yes                           8                      SCZ (64); Inpatients       ICD-10                -57.7 (PANSS) -11.2 yrs                                                                           34.1 (18-40)                                          56.5                                               Ø=ND (5-10)                      2
  Jiang 2017 (China)       C: 32 I: 32                                             Yes                           12                     SCZ (64); Inpatients       ICD-10                -52.5 (PANSS) -15.5 yrs                                                                           43.5 (18-60)                                          62.5                                               Ø=5 (FD)                         5
  Qu 2015 (China)          C: 23 I: 23                                             Yes                           8                      SCZ (46); Inpatients       ND                    -66.1 (PANSS) -5.8 yrs                                                                            42.5 (31-64)                                          56.5                                               Ø=ND (5-10)                      3

^a^Available data were extracted based on mean baseline value of each included trials.

Abbreviations: Both=inpatients and outpatients; C=control; DSM-IV=Diagnostic and Statistical Manual of Mental Disorders 4^th^ edition; FD=fixed dosage; I=intervention; ICD-10=the 10th revision of the International Statistical Classification of Diseases and Related Health Problems; NA=not applicable; ND=not description; PANSS=Positive and Negative Syndrome Scale; ROS=rosuvastatin; SCZ=schizophrenia; SzA=schizoaffective disorder; wks=weeks; yrs=years; Ø=mean.

###### 

Secondary outcomes

  Variables                           Study (subjects)   SMD/RR (95%CI)         *I^[@ref2]^*(%)   *P*-value
  ----------------------------------- ------------------ ---------------------- ----------------- -------------
  Total cholesterol (mg/dL)           2(164)             -2.00 (-2.79, -1.21)   76                **\<0.001**
  Triglycerides (mg/dL)               2(164)             -1.05 (-1.38, -0.72)                     **\<0.001**
  HDL-C (mg/dL)                       2(164)             0.14 (-0.16, 0.45)     0                 0.36
  Body weight (kg)                    3(208)             -0.40 (-1.29, 0.49)    89                0.38
  Waist circumference (cm)            3(208)             -0.43 (-1.31, 0.46)    89                0.34
  BMI (kg/m^[@ref2]^)                 2(164)             -0.34 (-1.23, 0.56)                      0.46
  Fasting glucose (mg/dL)             4(272)             -0.25 (-0.65, 0.15)    62                0.23
  Discontinuation due to any reason   2(128)             1.99 (0.36, 11.08)                       0.43
  Total psychopathology               3(172)             0.05 (-0.25, 0.34)     0                 0.77
  ADRs: Dizziness                     2(108)             0.54 (0.10, 2.97)      0                 0.48
      Dry mouth                       2(126)             0.87 (0.31, 2.43)      0                 0.79
      Insomnia                        3(172)             1.52 (0.44, 5.23)      0                 0.51
      Tachycardia                     2(108)             2.41 (0.37, 15.83)     0                 0.36
      Constipation                    3(172)             1.06 (0.33, 3.40)      0                 0.92
      Nausea/vomiting                 3(172)             1.23 (0.37, 4.06)      0                 0.73
      Extrapyramidal symptoms         2(126)             0.37 (0.06, 2.33)      0                 0.29

Abbreviations: ADRs=adverse drug reactions; BMI= body mass index; CI=confidence intervals; HDL-C= high density lipoprotein cholesterol; RR=risk ratio; SMD=Standard mean difference.

[^1]: ^\#^Equal contributions to this paper.
